Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai Acquires 21,000 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 21,000 shares of the stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average cost of $9.43 per share, for a total transaction of $198,030.00. Following the purchase, the chief technology officer now owns 21,000 shares of the company’s stock, valued at $198,030. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Immunome Trading Up 13.5 %

IMNM stock opened at $11.15 on Tuesday. The business’s 50-day moving average price is $12.49 and its two-hundred day moving average price is $13.55. Immunome, Inc. has a 1-year low of $6.93 and a 1-year high of $30.96. The firm has a market cap of $695.98 million, a PE ratio of -1.37 and a beta of 1.82.

Analysts Set New Price Targets

A number of analysts have weighed in on IMNM shares. Stephens started coverage on Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Piper Sandler dropped their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $28.83.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. FMR LLC grew its holdings in shares of Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after buying an additional 13,757 shares in the last quarter. Janus Henderson Group PLC lifted its position in Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after acquiring an additional 324,614 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Immunome by 113.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after acquiring an additional 1,194,451 shares during the period. Vanguard Group Inc. grew its position in Immunome by 16.1% during the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after buying an additional 279,712 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after buying an additional 1,191,774 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.